Reportedly, the phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study is also expected to assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
The company said that TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological malignancies as a monotherapy, and in combination with other anti-cancer therapies.
John Gill, president and CEO of TetraLogic, said: “This is an important milestone for our company and for cancer patients. The ability of TL32711 to antagonise Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”